Screener
Aquestive Therapeutics, Inc. AQST Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000030
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest expense related to the sale of future revenue | (60) | (59) |
| Interest income and other income, net | 83 | 713 |
| Net loss before income taxes | (8,057) | (22,930) |
| Net loss | $(8,057) | $(22,930) |
| Comprehensive loss | $(8,057) | $(22,930) |
| Loss per share attributable to common stockholders: | ||
| Basic and diluted (in dollars per share) | $(0.07) | $(0.24) |
| Weighted average common shares outstanding: |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s net income?
- Aquestive Therapeutics, Inc. (AQST) reported net income of -$8.06M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s net income changed year-over-year?
- Aquestive Therapeutics, Inc.'s net income increased by 64.9% year-over-year, from -$22.93M to -$8.06M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s net income has grown at a 4.4% compound annual growth rate (CAGR), from -$70.54M to -$83.78M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Aquestive Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude